YOLFTbeta
Shanghai MicuRx Pharmaceutical Co. Ltd. A

Shanghai MicuRx Pharmaceutical Co. Ltd. A

688373 · SHG · Healthcare / Drug Manufacturers - Specialty & Generic

5.06CNY-0.15 (-2.88%)

Price History

Full chart

Market Stats

Previous Close5.21
Open5.22
Day Range5.06 – 5.31
52-Week Range4.09 – 9.55
Volume10.94M
Market Cap3.79B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.22
Dividend Yield0.00%
Beta0.41
50-Day Avg5.34
200-Day Avg5.65

About

Shanghai MicuRx Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercialize drugs for unmet medical needs. It is developing Contezolid (MRX-I) and Contezoilid acefosamil (MRX-4) oxazolidinone antibiotics for multidrug-resistant gram-positive bacteria; MRX-8 MRX, a polymyxin antibiotic, to target multidrug-resistant Gram-negative bacteria; MRX-5 for multidrug-resistant gram-negative bacteria; MRX-7 for multidrug-resistant gram-positive bacteria; MRX-15 and MRX-17 to treat kidney disease; MRX-18 for the treatment of COVID-19; and MRX-23 for the treatment of tumour. The company was founded in 2007 and is based in Shanghai, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEODr. Yuan Zhengyu Ph.D.
  • Employees151
  • Headquarters53, Edison Road, Shanghai, China, China
  • Websitehttps://www.micurxchina.com

Leadership

  • Dr. Yuan Zhengyu Ph.D.CEO & Chairman · b. 1955
  • Mr. Xinghai WangDeputy GM, CTO & Director · b. 1981
  • Mr. Liang LuChairman of the Supervisory Board, Director of Quality & Compliance Dept. & Dep. GM of Ops. Mgmt. · b. 1983
  • Ms. Hong YuanDeputy GM & Chief Clinical Officer · b. 1977
  • Mr. Youyin XuDeputy GM & Head of Commercial Operations · b. 1968
  • Ms. Anna NieBoard Secretary · b. 1993
  • Ms. Cui GuoFinancial Controller & Head of Accounting Department
  • Mr. Liu JingianHead of Corporate Chemistry · b. 1986
  • Ms. Wang WenHead of Biological Department · b. 1962

Financials

Income Statement

Currency: CNY2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-7.66M48.21M90.78M130.27M141.77M
Growth (%)--+529.33%+88.31%+43.51%+8.83%
Cost of Revenue-578.38K8.82M16.70M22.41M21.53M
Gross Profit-7.08M39.38M74.08M107.87M120.24M
Gross Margin-92.45%81.70%81.61%82.80%84.81%
Operating Expense-270.02M271.45M509.95M544.39M364.54M
Operating Income-95.21M-262.94M-232.07M-435.87M-436.53M-244.30M
Operating Margin--3432.66%-481.40%-480.15%-335.09%-172.32%
EBITDA---195.92M-390.37M-408.70M-217.67M
EBITDA Margin---406.41%-430.04%-313.72%-153.54%
Net Income-86.33M-226.27M-220.30M-421.12M-440.72M-241.61M
Net Income Margin--2953.91%-456.99%-463.91%-338.31%-170.42%
R&D54.28M151.76M150.39M344.86M368.56M213.93M
R&D as % of Total Revenue-1981.17%311.97%379.90%282.92%150.90%
Interest Expense2.44M5.23M8.82M10.14M11.15M12.89M
Interest Expense % of Total Revenue-68.30%18.29%11.16%8.56%9.09%

Balance Sheet

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets-675.39M648.54M1.50B1.17B849.13M705.09M
Total Liabilities-55.16M210.17M283.10M334.56M410.16M499.55M
Total Equity-620.23M438.37M1.21B834.00M438.96M205.54M
Cash-226.51M145.52M151.09M166.31M386.26M316.10M

Cash Flow

Currency: CNY2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-89.34M-180.98M-240.01M-329.08M-447.18M-210.18M
Capital Expenditure799.55K22.91M12.18M7.66M914.77K549.09K
Free Cash Flow-90.14M-203.89M-252.18M-336.74M-448.10M-210.73M
Dividends Paid2.43M697.13K3.30M4.60M6.54M8.88M
FCF to OCF100.89%112.66%105.07%102.33%100.20%100.26%
Dividend Paid to FCF-2.69%-0.34%-1.31%-1.37%-1.46%-4.21%

Earnings

Report DateMar 24, 2023Apr 20, 2023
EPS Estimate--
EPS Actual-0.07-0.09
Surprise--
TimingAfter-hoursPre-market

Key Statistics & Ratios

Market Cap3.79B
Enterprise Value3.92B
Trailing P/E0.00
Forward P/E0.00
Price / Sales23.08
Price / Book24.24
EPS-0.22
Book Value0.248
Revenue (TTM)164.33M
Gross Profit (TTM)141.00M
EBITDA-146.21M
Profit Margin-85.50%
Operating Margin-39.63%
Return on Equity-58.99%
Return on Assets-13.21%
Shares Outstanding656.23M
Shares Float422.47M
Beta0.41
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%